American Society of HematologyYour Approach to Treating this Transplant-Ineligible Patient with Ph+ ALL?

In ASH Clinical News, Dr. Geoffrey Uy, a professor in the Oncology Division at Washington University School of Medicine in St. Louis, discusses treatment options for a transplant-ineligible patient who has Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). The patient under review is a 61-year-old female diagnosed with Ph+ ALL who has multiple comorbidities and […]

American Society of HematologyHow I Treat Pediatric Acute Myeloid Leukemia

In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors.

Everyday HealthClinical Challenge: Hematologic Malignancy and COVID-19

The inaugural report of the ASH Research Collaborative (RC) COVID-19 Registry for Hematology, published in Blood Advances, is based on an analysis of the first 250 patients with both hematologic malignancy and COVID-19 registered from 74 countries. The analysis showed that the mortality risk (28% overall and increased to 42% among hospitalized patients with COVID-19) […]

American Society of HematologyMarrow or Peripheral Blood for Allogeneic Transplant: Are We Ignoring the Data?

Despite peripheral blood making up 80% of all of hematopoietic cell transplants, there are similar rates of overall survival, disease-free survival, and transplant-related mortality when comparing marrow and peripheral blood as graft sources. Chronic graft-versus-host disease (GVHD) and cytokine release syndrome (CRS) are more significant in those who received peripheral blood, yet the standard of […]

Millennium Medical PublishingHighlights in Myelodysplastic Syndromes From the 62nd ASH Annual Meeting and Exposition

This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results from various trials and studies, including MEDALIST, DACOTA, P-2001, M15-531, ACE-536-MF-001, Sintra-REV, and COMMANDS.

American Society of HematologyASH 2021 Guidelines for Management of Venous Thromboembolism: Prevention and Treatment in Patients with Cancer

These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of venous thromboembolism (VTE)  – a common complication among patients with cancer who are at a markedly increased risk for morbidity and mortality.

Millennium Medical PublishingHighlights in Chronic Lymphocytic Leukemia From the 62nd ASH Annual Meeting and Exposition

This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others. 

American Society of HematologyASH/ISTH/NHF/WFH 2021 Guidelines on the Management of von Willebrand Disease

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.

American Society of HematologyASH Annual Meeting: Does High-Dose Methotrexate Protect the CNS in High-Risk DLBCL?

The possible answer was presented during the 2020 ASH Annual Meeting, bringing into question whether current recommendations for prophylactic intravenous high-dose methotrexate — the most widely adopted method for CNS relapse prevention — are appropriate for all patients at high risk of a CNS relapse.

Mayo ClinicA Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis

In this symposium preceding the ASH Annual Meeting on 12/4/20, the overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. The speakers will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.